98 related articles for article (PubMed ID: 26972330)
1. Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
Poondru S; Chaves J; Yuen G; Parker B; Conklin E; Singh M; Nagata M; Gill S
Cancer Chemother Pharmacol; 2016 Apr; 77(4):829-37. PubMed ID: 26972330
[TBL] [Abstract][Full Text] [Related]
2. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Fassnacht M; Berruti A; Baudin E; Demeure MJ; Gilbert J; Haak H; Kroiss M; Quinn DI; Hesseltine E; Ronchi CL; Terzolo M; Choueiri TK; Poondru S; Fleege T; Rorig R; Chen J; Stephens AW; Worden F; Hammer GD
Lancet Oncol; 2015 Apr; 16(4):426-35. PubMed ID: 25795408
[TBL] [Abstract][Full Text] [Related]
3. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
[TBL] [Abstract][Full Text] [Related]
4. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
5. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
[TBL] [Abstract][Full Text] [Related]
6. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
7. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
Wickremsinhe ER; Hynes SM; Palmieri MD; Mitchell MI; Abraham TL; Rehmel JF; Chana E; Jost LM; Cassidy KC
Xenobiotica; 2014 Sep; 44(9):827-41. PubMed ID: 24666335
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
10. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Davis SL; Eckhardt SG; Diamond JR; Messersmith WA; Dasari A; Weekes CD; Lieu CH; Kane M; Choon Tan A; Pitts TM; Leong S
Oncologist; 2018 Dec; 23(12):1409-e140. PubMed ID: 30139840
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
[TBL] [Abstract][Full Text] [Related]
14. A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.
Goldinger SM; Rinderknecht J; Dummer R; Kuhn FP; Yang KH; Lee L; Ayala RC; Racha J; Geng W; Moore D; Liu M; Joe AK; Bazan SP; Grippo JF
Pharmacol Res Perspect; 2015 Mar; 3(2):e00113. PubMed ID: 25729580
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
[TBL] [Abstract][Full Text] [Related]
16. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
17. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
18. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
